Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M, Rotevatn EØ, Rosthøj S, Nersting J, Abrahamsson J, Appell ML, Bergan S, Bechensteen AG, Harila-Saari A, Heyman M, Jonsson OG, Maxild JB, Niemi M, Söderhäll S, Schmiegelow K; Nordic Society of Paediatric Haematology, Oncology. Levinsen M, et al. Among authors: abrahamsson j. Pediatr Blood Cancer. 2014 May;61(5):797-802. doi: 10.1002/pbc.24921. Epub 2014 Jan 3. Pediatr Blood Cancer. 2014. PMID: 24395436
In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Abrahamsson J, Behrendtz M, Heldrup J, Jacobsson S, Li A, Olofsson T, Porwit A, Söderhäll S, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: abrahamsson j. Leuk Res. 2009 Jan;33(1):46-53. doi: 10.1016/j.leukres.2008.06.012. Epub 2008 Jul 17. Leuk Res. 2009. PMID: 18639340
Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Frandsen TL, Abrahamsson J, Lausen B, Vettenranta K, Heyman M, Behrentz M, Castor A, Wehner PS, Frost BM, Andersen EW, Schmiegelow K. Frandsen TL, et al. Among authors: abrahamsson j. Br J Haematol. 2011 Oct;155(2):244-7. doi: 10.1111/j.1365-2141.2011.08835.x. Epub 2011 Aug 18. Br J Haematol. 2011. PMID: 21848519 Free article. Clinical Trial.
Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia.
Staffas A, Kanduri M, Hovland R, Rosenquist R, Ommen HB, Abrahamsson J, Forestier E, Jahnukainen K, Jónsson ÓG, Zeller B, Palle J, Lönnerholm G, Hasle H, Palmqvist L, Ehrencrona H; Nordic Society of Pediatric Hematology and Oncology (NOPHO). Staffas A, et al. Among authors: abrahamsson j. Blood. 2011 Nov 24;118(22):5905-13. doi: 10.1182/blood-2011-05-353185. Epub 2011 Oct 3. Blood. 2011. PMID: 21967978 Free article.
Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004.
Hasle H, Abrahamsson J, Forestier E, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Hasle H, et al. Among authors: abrahamsson j. Blood. 2012 Aug 2;120(5):978-84. doi: 10.1182/blood-2012-03-416701. Epub 2012 Jun 22. Blood. 2012. PMID: 22730539 Free article. Clinical Trial.
Outcome of poor response paediatric AML using early SCT.
Wareham NE, Heilmann C, Abrahamsson J, Forestier E, Gustafsson B, Ha SY, Heldrup J, Jahnukainen K, Jónsson ÓG, Lausen B, Palle J, Zeller B, Hasle H. Wareham NE, et al. Among authors: abrahamsson j. Eur J Haematol. 2013 Mar;90(3):187-94. doi: 10.1111/ejh.12051. Epub 2013 Jan 20. Eur J Haematol. 2013. PMID: 23215948
197 results